Advances in ultrasound-targeted microbubble-mediated gene therapy for liver fibrosis.
10.1016/j.apsb.2017.02.004
- Author:
Cuiyuan HUANG
1
;
Hong ZHANG
1
;
Ruidan BAI
1
Author Information
1. Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan 430060, China.
- Publication Type:Journal Article
- Keywords:
Cavitation;
Gene delivery;
Gene therapy;
Liver fibrosis;
Sonoporation;
Ultrasound-targeted microbubbles
- From:
Acta Pharmaceutica Sinica B
2017;7(4):447-452
- CountryChina
- Language:English
-
Abstract:
Hepatic fibrosis develops as a wound-healing scar in response to acute and chronic liver inflammation and can lead to cirrhosis in patients with chronic hepatitis B and C. The condition arises due to increased synthesis and reduced degradation of extracellular matrix (ECM) and is a common pathological sequela of chronic liver disease. Excessive deposition of ECM in the liver causes liver dysfunction, ascites, and eventually upper gastrointestinal bleeding as well as a series of complications. However, fibrosis can be reversed before developing into cirrhosis and has thus been the subject of extensive researches particularly at the gene level. Currently, therapeutic genes are imported into the damaged liver to delay or prevent the development of liver fibrosis by regulating the expression of exogenous genes. One technique of gene delivery uses ultrasound targeting of microbubbles combined with therapeutic genes where the time and intensity of the ultrasound can control the release process. Ultrasound irradiation of microbubbles in the vicinity of cells changes the permeability of the cell membrane by its cavitation effect and enhances gene transfection. In this paper, recent progress in the field is reviewed with emphasis on the following aspects: the types of ultrasound microbubbles, the construction of an ultrasound-mediated gene delivery system, the mechanism of ultrasound microbubble-mediated gene transfer and the application of ultrasound microbubbles in the treatment of liver fibrosis.
